Related Experiment Video
Updated: Jun 29, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.4K
Advancing Guideline-Directed Medical Therapy in Heart Failure: Overcoming Challenges and Maximizing Benefits
Zixi Zhang1, Cancan Wang2, Tao Tu1
1Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, 139 Renmin Road, Furong District, Changsha, 410011, Hunan Province, People's Republic of China.
Summary
Delayed titration of guideline-directed drug therapy (GDMT) in heart failure (HF) impacts patient outcomes. Optimizing GDMT initiation and individualized titration is crucial for improving prognosis and treatment effectiveness.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Delayed initiation and titration of guideline-directed drug therapy (GDMT) are significant challenges in managing heart failure (HF).
- These delays are influenced by various factors and are associated with poorer patient prognoses.
- Individualized patient characteristics necessitate tailored adjustments in GDMT titration strategies.
Purpose of the Study:
- To review current challenges in GDMT implementation for heart failure.
- To scrutinize GDMT titration considerations in distinct HF patient subsets.
- To enhance the adoption and effectiveness of GDMT in heart failure management.
Main Methods:
- Literature review of current challenges and titration considerations in GDMT for heart failure.
- Analysis of factors influencing delayed GDMT titration.
- Examination of HF patient subsets requiring individualized titration approaches.
Main Results:
- Delayed GDMT titration is a complex issue linked to poor heart failure prognosis.
- Individualized titration based on patient characteristics is essential.
- Current implementation faces significant challenges impacting treatment effectiveness.
Conclusions:
- Prompt initiation and appropriate titration of GDMT are critical for all clinicians managing heart failure.
- A novel, integrated management strategy involving a multidisciplinary team (cardiologists, NPs, pharmacists, patients) is proposed.
- This team-based approach aims to improve GDMT promotion and implementation for better heart failure outcomes.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162